Valley National Advisers’s AstraZeneca AZN Stock Holding History

Valley National Advisers’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.66M	Sell	13,495 -129	-0.9%	-$24.9K	0.34%	55
2025 Q4	$2.5M	Sell	13,624 -737	-5%	-$129K	0.35%	59
2025 Q3	$2.2M	Buy	14,361 +2,087	+17%	+$316K	0.34%	69
2025 Q2	$1.71M	Buy	12,274 +64	+0.5%	+$8.97K	0.28%	91
2025 Q1	$1.79M	Buy	12,210 +475	+4%	+$68.7K	0.32%	79
2024 Q4	$1.54M	Buy	11,735 +254	+2%	+$35.6K	0.28%	96
2024 Q3	$1.79M	Buy	11,481 +11,306	+6,461%	+$1.83M	0.32%	84
2024 Q2	$27K	Hold	175	–	–	﹤0.01%	469
2024 Q1	$23K	Sell	175 -35	-17%	-$4.63K	﹤0.01%	501
2023 Q4	$28K	Buy	210 +35	+20%	+$4.55K	﹤0.01%	486
2023 Q3	$24K	Hold	175	–	–	﹤0.01%	476
2023 Q2	$26K	Hold	175	–	–	﹤0.01%	467
2023 Q1	$27K	Hold	175	–	–	﹤0.01%	468
2022 Q4	$24K	Hold	175	–	–	﹤0.01%	472
2022 Q3	$20K	Hold	175	–	–	﹤0.01%	489
2022 Q2	$23K	Hold	175	–	–	﹤0.01%	451
2022 Q1	$23K	Sell	175 -398	-69%	-$47.7K	﹤0.01%	481
2021 Q4	$67K	Sell	573 -164	-22%	-$19.3K	0.01%	326
2021 Q3	$89K	Hold	737	–	–	0.02%	292
2021 Q2	$88K	Hold	737	–	–	0.02%	293
2021 Q1	$73K	Sell	737 -7	-0.9%	-$704	0.01%	302
2020 Q4	$74K	Buy	744 +528	+244%	+$55.9K	0.02%	285
2020 Q3	$24K	Hold	216	–	–	0.01%	377
2020 Q2	$23K	Hold	216	–	–	0.01%	380
2020 Q1	$19K	Sell	216 -84	-28%	-$7.91K	0.01%	384
2019 Q4	$30K	Buy	300 +80	+36%	+$7.53K	0.01%	367
2019 Q3	$20K	Hold	220	–	–	0.01%	417
2019 Q2	$18K	Hold	220	–	–	﹤0.01%	411
2019 Q1	$18K	Sell	220 -76	-26%	-$5.99K	0.01%	405
2018 Q4	$22K	Sell	296 -12	-4%	-$937	0.01%	347
2018 Q3	$24K	Hold	308	–	–	0.01%	331
2018 Q2	$22K	Hold	308	–	–	0.01%	327
2018 Q1	$22K	Hold	308	–	–	0.01%	321
2017 Q4	$21K	Hold	308	–	–	0.01%	320
2017 Q3	$21K	Sell	308 -204	-40%	-$12.9K	0.01%	326
2017 Q2	$35K	Hold	512	–	–	0.01%	275
2017 Q1	$32K	Sell	512 -912	-64%	-$53.1K	0.01%	282
2016 Q4	$78K	Sell	1,424 -67	-4%	-$3.8K	0.04%	214
2016 Q3	$98K	Buy	1,491 +175	+13%	+$11.4K	0.05%	175
2016 Q2	$79K	Hold	1,316	–	–	0.04%	197
2016 Q1	$74K	Hold	1,316	–	–	0.04%	202
2015 Q4	$89K	Hold	1,316	–	–	0.05%	186
2015 Q3	$84K	Hold	1,316	–	–	0.05%	192
2015 Q2	$84K	Hold	1,316	–	–	0.05%	202
2015 Q1	$90K	Buy	1,316 +290	+28%	+$20.1K	0.05%	180
2014 Q4	$61K	Buy	+1,026	New	+$73.5K	0.05%	153

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Valley National Advisers's AZN Position: Q1 2026 in Review

Valley National Advisers reduced its AstraZeneca (AZN) stake by 0.95% in Q1 2026, selling an estimated $24.9K and leaving 13,495 shares worth $2.66M. The position accounts for 0.34% of the portfolio, ranked #55.

Valley National Advisers first reported a position in AZN in Q4 2014 and has held it in 46 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Valley National Advisers held 13,495 shares of AstraZeneca worth $2.66M as of Q1 2026.
Valley National Advisers sold 129 AstraZeneca shares in Q1 2026, an estimated $24.9K.
AstraZeneca made up 0.34% of Valley National Advisers's portfolio in Q1 2026, its #55 holding.
Valley National Advisers first reported a position in AstraZeneca in Q4 2014 and has held it in 46 quarters since.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Valley National Advisers's 13F filing for Q1 2026, filed 15 Apr 2026.